<DOC>
	<DOCNO>NCT02292966</DOCNO>
	<brief_summary>The purpose study examine whether neurocognitive impairment experience patient chronic hepatitis C virus ( HCV ) infection reverse treat HCV , new combination direct act antiviral drug ( daclatasvir ( DCV ) , asunaprevir ( ASV ) beclabuvir ( BCV ) ) . The study assess effect HCV central nervous system ( CNS ) assess neurocognitive function brain injury prior treatment , compare end treatment , 4 , 12 24 week treatment .</brief_summary>
	<brief_title>Impact HCV Treatment Neurocognitive Functions Brain Metabolism</brief_title>
	<detailed_description>This study evaluate effect DCV/ASV/BCV neurocognitive functioning brain metabolite concentration frontal white matter basal ganglia people chronic HCV genotype 1 infection , comparison baseline post-treatment parameter . This open label single arm multi-centre study . All participant receive daclatasvir ( 30mg ) , asunaprevir ( 200mg ) beclabuvir ( 75mg ) fixed-dose combination oral tablet twice daily administration food . Duration treatment 12 week subject follow 24 week observational follow-up .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Aged 18 65 year Chronic HCV infection document positive HCV RNA screen positive HCV RNA antiHCV antibody least 6 month prior screen HCV genotype 1 mixed subtype , indeterminate subtype variant genotype 1 permissible Nonadvanced cirrhotic define FibroScan ≤9.6 kPA screen HCV treatment naïve Seronegative HIV HBsAg HCV RNA level ≥104 IU/mL ( 10,000 IU/mL ) Body Mass Index ( BMI ) 18 35 kg/m2 Women childbearing potential ( WOCBP ) must : . Have negative serum urine pregnancy test ( minimum sensitivity 25 IU/mL equivalent unit HCG ) within 24 hour prior start study drug ii . Not breastfeed iii . Agree follow instruction method contraception duration treatment five week posttreatment completion Men sexually active WOCBP must agree follow instruction method contraception duration treatment 14 week posttreatment completion Sufficient proficiency English complete neurocognitive assessment , judge investigator Target disease Infected HCV genotype 1 Medical history concurrent diseases Current hazardous consumption alcohol , define AUDITC score ≥4 men ≥3 woman Illicit substance use , identify urinary drug test screen Past history non HCVrelated CNS disorder , include seizure traumatic brain injury Currently SSRI neuropsychiatric therapy Liver organ transplant cornea hair Current known history cancer ( except situ carcinoma cervix adequately treat basal squamous cell carcinoma skin ) within 5 year prior enrolment Evidence medical condition contribute chronic liver disease HCV ( , limit : hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcohol liver disease ) Any gastrointestinal disease surgical procedure may impact absorption study drug ( subject cholecystectomy permit enter study ) Known history coagulopathy include , limited , hemophilia Uncontrolled diabetes define HbA1c &gt; 7 % screening Confirmed , uncontrolled hypertension ( screen systolic blood pressure ≥160 mmHg diastolic blood pressure ≥100 mmHg exclude unless discuss study medical monitor ) Inability tolerate oral medication Poor venous access Any medical , psychiatric and/or social reason , opinion investigator would make subject inappropriate study Physical Laboratory Test Findings ALT ≥ 5 x ULN Total Bilirubin ≥ 34 µmol/L ( ≥ 2 mg/dl ) , unless subject documented history Gilbert 's disease INR ≥ 1.3 Albumin &lt; 3.5 g/dL ( 35g/L ) Platelets &lt; 100 x 109 cells/L ANC &lt; 0.75 x 109 cells/L Hemoglobin &lt; 10 g/dL ( 100g/L ) Creatinine clearance ( CrCL ) ≤ 50 mL/min Alpha fetoprotein ( AFP ) &gt; 50ng/mL QTcF QTcB &gt; 580mSec Positive HBsAg , HIV1 HIV2 Ab Allergies Adverse Drug Reaction History hypersensitivity drug similar biochemical structure DCV , ASV BCV Any criterion know contraindication would exclude subject receive DCV , ASV BCV Prohibited treatment and/or Therapies Exposure investigational drug placebo within 4 week study drug administration Refer 5.5 prohibit and/or restrict treatment posttreatment Sex reproductive status Males females unable meet requirement outline Inclusion Criterias 9 10 Other Exclusion Criteria Prisoners subject involuntarily incarcerate Subjects compulsorily detain treatment either psychiatric physical ( e.g . infection disease ) illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Asunaprevir</keyword>
	<keyword>Daclatasvir</keyword>
	<keyword>Beclabuvir</keyword>
	<keyword>Neurocognitive function</keyword>
	<keyword>Brain metabolite</keyword>
	<keyword>Direct act antiviral therapy</keyword>
</DOC>